[DOI] [PMC free article] [PubMed] [Google Scholar] 278.Udovicic M., Sever M., Kavur L., Loncaric K., Barisic I., Balenovic D., Zivanovic Posilovic G., Strinic D., Uzun S., Batelja Vuletic L., et al

Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models

The corresponding pharmacokinetic parameters are listed as follows: T max = 0.167 h, C max = 155 11.8 ng Eq./ml, AUC 0t = 4945 417 h ng Eq./ml, AUC 0 = 12956 2074 hng Eq./ml, average residence time (MRT 0-t ) of plasma total radioactivity = 33.2 1.03 h, and t 1/2 = 102 h (Table 9)
Why patients choose this treatment Every program is designed to deliver safe, effective results with the support of licensed providers and the convenience of home delivery
beta-blockers and the eye: An overview
When a person with Down syndrome has vitamin B12 and/or folate deficiency, the increase in the homocysteine level may not be great enough to overcome this starting low value of homocysteine